Who is sponsoring NCT01110226?

NCT01110226 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT01110226?

Interventions in NCT01110226: KML-001, Cisplatin.

What condition does NCT01110226 study?

NCT01110226 studies Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Platinum Responsive Malignancies.

Is NCT01110226 still recruiting?

NCT01110226 is currently terminated. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT01110226: 0805GCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies

Terminated Phase 1 Last updated 17 March 2020

What this trial tests

Phase 1 trial testing KML-001 in Non-Small Cell Lung Cancer, Small Cell Lung Cancer in 23 participants. Terminated before completion.

Timeline

27 April 2010

Primary endpoint
22 October 2015

27 October 2015

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	27 April 2010
Primary completion	22 October 2015
Estimated completion	27 October 2015
Sites	1 location across United States

Drugs / interventions tested

KML-001 — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer, Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer, Small Cell Lung Cancer →
Platinum Responsive Malignancies — all drugs for Platinum Responsive Malignancies →

Sponsor

University of Maryland, Baltimore

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer, Small Cell Lung Cancer or Platinum Responsive Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of investigational drugs that can be safely tolerated and to define the side effects that limit the dose. The drug administered in this study is KML-001. It is a highly soluble, orally available arsenic agent. It is currently being tested to determine its effects on telomerase activity. In other words, the purpose of this research study is to find the highest dose of KML001, that can be given without causing severe side effects when it is combined with a standard, commercially available anti-cancer drug called cisplatin.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics.
Tao HY, Zhao CY, Wang Y, Sheng WJ, et al · · 2024 · cited 5× · PMID 38708177 · DOI 10.2147/ijn.s448556
Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.
Ouyang D, Chen R, Xie H, Yang X, et al · · 2025 · cited 1× · PMID 41311391 · DOI 10.1016/j.apsb.2025.09.007

Verify or expand the search:

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01110226 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01110226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing